Board Changes
16/01/2025 07:00
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250116:nRSP4997Ta&default-theme=true
RNS Number : 4997T Niox Group PLC 16 January 2025
NIOX Group plc
Board Changes
Oxford, UK - 16 January 2025: NIOX Group plc (("NIOX", the "Company" or the
"Group"; AIM: NIOX), a medical device company focused on point of care asthma
diagnosis, monitoring and management, is pleased to announce the following
board changes.
Ian Johnson, currently Executive Chairman, will move to Non-Executive Chairman
with effect from the 2025 AGM, which is expected to be held on 14 May 2025.
Jonathan Emms, currently Chief Operating Officer, has been appointed Chief
Executive Officer with immediate effect.
Michael Roller, currently Chief Financial Officer, has indicated to the Board
that he intends to retire with effect from the 2025 AGM, which is expected to
be held on 14 May 2025. Michael will remain available to the Group as a
consultant, as and when required.
Sarah Duncan, currently Group Financial Controller and Company Secretary, will
succeed Michael as Chief Financial Officer on his retirement. Sarah has worked
for the Group since 2018.
Sarah qualified as a Chartered Accountant with PwC and subsequently worked at
Unipart for two years prior to joining the Group as Group Finance Manager in
2018 and becoming Company Secretary in November 2020. She was promoted to
her current role in April 2024.
Ian Johnson, NIOX's Executive Chairman, said: "The current executive team have
worked together since the beginning of 2020 and have led the successful
turnaround of the business. Jonathan's and Sarah's promotions from within the
business are well deserved and provide stability and continuity. I
congratulate both and wish them every success."
Additional information
The following information is being disclosed pursuant to Rule 17 and paragraph
(g) of Schedule 2 of the AIM Rules for Companies in relation to the
appointment of Sarah Elizabeth Duncan, aged 33, to the Board.
Sarah Duncan has been a director or partner of the following companies or
partnerships during the five years preceding the date of this announcement:
Current directorships: Niox Healthcare Limited, Niox Limited, JMD Orthopaedics
Limited
Past directorships (last five years): None
As at the date of this announcement, Sarah Duncan owns no shares in the
Company and holds options over 506,219 shares in the Company.
Save as set out above there are no further disclosures required pursuant to
Rule 17 or Schedule Two, paragraph (g) of the AIM Rules for Companies.
Contacts
NIOX Tel: +44 (0) 1865 405 560
Ian Johnson, Executive Chairman
Jonathan Emms, Chief Executive Officer
Michael Roller, Chief Financial Officer
Singer Capital Markets (Nominated Adviser and joint broker) Tel: +44 (0) 20 7496 3000
Jen Boorer / James Fischer / James Todd
Investec Bank plc (joint broker) Tel: +44 (0) 20 7597 5970
Ben Lawrence / Lydia Zychowska
About NIOX
Our mission is to improve asthma diagnosis, monitoring and management by
greater patient access to FeNO testing. Asthma is one of the biggest
healthcare issues globally with 340 million sufferers, many of whom are
undiagnosed or are misdiagnosed. The Group is engaged in the design,
development, and commercialisation of medical devices for the measurement of
FeNO, a precise biomarker for asthma. Our market leading device, NIOX VERO®,
is increasingly recognised by healthcare professionals as an important tool to
improve the diagnosis and management of asthma. NIOX VERO® is also the device
of choice by leading clinical research organisations for respiratory studies.
NIOX provides products and services via its direct sales organisation and
extensive distributor network in 50 countries. For more information, please
visit www.niox.com (http://www.niox.com)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END BOAGPUACGUPAGMA